Dosage Chart

Glow Dosage Chart

Glow dosage chart — how to reconstitute the 70 mg blend, tiered subcutaneous protocols with per-component unit math, and the TB-500 accumulation caveat.

Last updated · 2026-08-04
Source this stack
GHK-Cu12 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →
BPC-15712 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →
TB-50012 vetted vendors

Save 15% with code VIALBASE

See all 12 sources →

VialBase may earn a commission on partner links — never at extra cost to you. Disclosure.

Reconstitution

70 mg Glow vial (GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg) in 2 mL bacteriostatic water

Reconstituted at 70 mg / 2 mL, the blend is 35 mg/mL. On a U-100 syringe, 10 units = 0.1 mL = 3.5 mg of blend; GHK-Cu sits at 25 mg/mL, BPC-157 and TB-500 at 5 mg/mL each.

The Glow dosage chart covers how to reconstitute the 70 mg blend and the tiered subcutaneous protocols below, with the per-component milligram math for each draw. Glow is a fixed-ratio blend — you titrate the vial, not the individual peptides — so the tiers move the whole blend up or down together.

Dosage protocols

Starter (titration)

10 units · 0.1 mL · 3.5 mg blend
Once daily, 3–5 days
  • GHK-Cu 2.5 mg
  • BPC-157 500 mcg
  • TB-500 500 mcg
Cycle: Assess tolerance before increasing

Start low to gauge tolerance before the standard draw. 10 units delivers BPC-157 and TB-500 at 500 mcg each — in range for their typical standalone doses — with 2.5 mg of GHK-Cu.

TB-500-moderated cadence

20 units · 0.2 mL · 7 mg blend
Every other day, or 4–5 days/week
  • GHK-Cu 5 mg / dose
  • BPC-157 1 mg / dose
  • TB-500 1 mg / dose
Cycle: 4–6 weeks, then washout

Because TB-500 has a ~14-day half-life, daily blend dosing accumulates more TB-500 than a typical 2–5 mg/week standalone schedule. Dosing every other day moderates cumulative TB-500 while keeping the shorter-half-life components (GHK-Cu, BPC-157) effective.

Your vial, your numbers

Different vial size or water volume? Recalculate your exact draw.

Glow blend

Syringe Size

Draw to mark

20u(0.200 mL)

Concentration

35000 mcg / mL

For research purposes only. Verify all calculations independently before use.

020406080100
20u
100u syringe

From vial to injection

  1. Sanitize Wipe the vial stopper and the bacteriostatic-water vial stopper with fresh alcohol swabs and let them dry.
  2. Draw the diluent Draw 2 mL of bacteriostatic water into a reconstitution syringe.
  3. Add water slowly Insert the needle at an angle and let the water run down the inside wall of the peptide vial — do not spray it directly onto the powder.
  4. Swirl, don't shake Gently swirl or roll the vial until fully dissolved. Never shake — agitation can degrade the peptides.
  5. Draw your dose With a U-100 insulin syringe, draw to the unit mark for your tier (10 units = 0.1 mL, 20 units = 0.2 mL).
  6. Inject subcutaneously Inject into subcutaneous fat (abdomen or flank), rotating sites. Store the reconstituted vial at 2–8 °C and use within 28 days.

Feeling something? Check here

Normal — expected
  • Mild, transient injection-site redness, itch or a small welt that fades within an hour
  • A brief flushing or warmth after the copper-peptide component
  • Temporary fatigue in the first few days as you titrate
Back off & reassess
  • Persistent headache, lightheadedness or nausea that doesn't settle — back off to the starter draw and reassess
  • Injection-site lumps, swelling or bruising that linger more than a day — rotate sites and check technique
Stop & seek care
  • Chest tightness, difficulty breathing, or facial/throat swelling — stop immediately and seek emergency care (possible allergic reaction)
  • Signs of infection at an injection site — spreading redness, heat, pus, fever
  • Any new or growing lump elsewhere — peptides that drive tissue growth are contraindicated with active or suspected cancer

General subcutaneous-peptide safety guidance; TB-500 tolerability anchored to a phase-1 thymosin β4 trial (54 healthy volunteers, 0.05–25 mcg/kg IV, mild-to-moderate adverse events, no dose-limiting toxicity).

This self-check is educational, not a diagnosis. When in doubt, stop dosing and consult a qualified healthcare provider.

Frequently Asked Questions

How do you reconstitute and dose the Glow blend?
Reconstitute the 70 mg vial (GHK-Cu 50 mg + BPC-157 10 mg + TB-500 10 mg) with 2 mL bacteriostatic water (35 mg/mL blend). Inject subcutaneously once daily, starting near 10 units (0.1 mL) to assess tolerance and working up to 10–20 units. Store reconstituted blend at 2–8 °C and use within 28 days.
What is the difference between Glow and KLOW?
Glow is GHK-Cu + BPC-157 + TB-500 for skin radiance, hair regrowth, collagen synthesis, and healing. KLOW adds KPV, a dedicated anti-inflammatory tripeptide, making it better for inflammatory skin, gut issues, or autoimmune-adjacent concerns. The two blends otherwise share the same GHK-Cu-dominant base.
How much of each peptide is in a 20-unit Glow dose?
At 70 mg / 2 mL, a 20-unit (0.2 mL) draw delivers GHK-Cu 5 mg, BPC-157 1 mg, and TB-500 1 mg. A 10-unit draw delivers half of each: GHK-Cu 2.5 mg and 500 mcg of BPC-157 and TB-500.
Is Glow FDA-approved?
No. All three peptides are research-use-only in the US and none is on the 503A bulks list or in any FDA interim category that would permit compounding. Community dosing guides are a starting point, not medical advice. Avoid with active cancer or during pregnancy.

Sources

Full Glow stack profile →